Rafferty Asset Management
CHRS icon

Rafferty Asset Management’s Coherus Oncology CHRS Stock Holding History

Rafferty Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-876,332
Closed -$3.28M – 1077
2023
Q3 		$3.28M Buy
+876,332
New +$4.05M 0.02% 480
2023
Q2 		– Sell
-400,569
Closed -$2.74M – 1100
2023
Q1 		$2.74M Sell
400,569
-68,813
-15% -$534K 0.02% 525
2022
Q4 		$3.72M Buy
469,382
+200,546
+75% +$1.54M 0.03% 440
2022
Q3 		$2.58M Buy
268,836
+38,730
+17% +$392K 0.03% 454
2022
Q2 		$1.67M Sell
230,106
-42,181
-15% -$367K 0.02% 518
2022
Q1 		$3.52M Buy
272,287
+90,840
+50% +$1.16M 0.02% 466
2021
Q4 		$2.9M Buy
181,447
+57,458
+46% +$1M 0.02% 546
2021
Q3 		$1.99M Sell
123,989
-55,906
-31% -$819K 0.01% 636
2021
Q2 		$2.49M Sell
179,895
-25,151
-12% -$356K 0.02% 604
2021
Q1 		$3M Buy
205,046
+162,719
+384% +$2.76M 0.02% 495
2020
Q4 		$736K Sell
42,327
-58,629
-58% -$1.04M 0.01% 594
2020
Q3 		$1.85M Buy
100,956
+41,571
+70% +$773K 0.02% 442
2020
Q2 		$1.06M Buy
59,385
+45,524
+328% +$771K 0.01% 529
2020
Q1 		$225K Sell
13,861
-122,540
-90% -$2.26M 0.01% 497
2019
Q4 		$2.46M Sell
136,401
-18,555
-12% -$342K 0.04% 291
2019
Q3 		$3.14M Buy
154,956
+50,800
+49% +$1.01M 0.05% 222
2019
Q2 		$2.3M Buy
104,156
+12,894
+14% +$224K 0.04% 350
2019
Q1 		$1.25M Buy
+91,262
New +$1.22M 0.02% 506

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's CHRS Position: Q4 2023 in Review

Rafferty Asset Management sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 876,332 shares — an estimated $3.28M sold.

Rafferty Asset Management first reported a position in CHRS in Q1 2019 and held it in 18 quarters. The position peaked at $3.72M in Q4 2022. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Rafferty Asset Management reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 876,332 Coherus Oncology shares in Q4 2023, an estimated $3.28M.
  • Rafferty Asset Management first reported a position in Coherus Oncology in Q1 2019 and held it in 18 quarters.
  • Rafferty Asset Management's Coherus Oncology position peaked at $3.72M in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.